[Results of the treatment of cancer of the movable part of the tongue with clinically intact regional lymph nodes]. / Rezul'taty lecheniia raka podvizhnoi chasti iazyka s klinicheski intaktnymi regionarnymi limfaticheskimi uzlami.

A study was made of the frequency of metastatic spreading to the regional neck lymph nodes and long-term results of therapy of 126 patients with cancer of the movable part of the tongue with clinically intact regional lymph nodes of the neck. With regard to an employed modality (irradiation, alone and in combination with surgery, surgery and observation) the frequency of metastatic spreading to the neck lymph nodes was 20, 7, 17, and 34%, respectively, and 22% for the whole group. The 5-year survival rates were 79, 50, 49, and 67%, and 61% for the whole group. The main cause of death in 40% of the patients was a primary tumor recurrence versus 17% following the other modalities.

[Causes of late diagnosis of nasopharyngeal cancer]. / Prichiny pozdnei diagnostiki raka nosoglotki.

By the onset of specific therapy of 240 patients with nasopharyngeal cancer 96.6% of them were in stage III (20%) and stage IV (76.6%) of the disease. The causes of delayed diagnosis and therapy included inadequate oncology concern of out-patient physicians, careless attitude of most patients towards their own health condition, low quality of physical examinations and limited diagnostic facilities.

[Long-term results of complex and combined treatment of locally advanced cancer of the oral mucosa]. / Otdalennye rezul'taty kompleksnogo i kombinirovannogo lecheniia mestno-rasprostranennogo raka slizistoi obolochki polosti rta.

The analysis of data on 93 cases of stage III-IV cancer of the oral mucosa showed the superiority of combined treatment over complex in terms of five-year survival: 47 and 20%, respectively (p less than 0.01). However, no significant difference in respect to that parameter was established between the combined treatment group and patients rendered disease-free with complex therapy: 47 and 40%, respectively (p greater than 0.05). In the whole group studied, five-year survival rate was 32 +/- 5%; it was 37 +/- 6 and 25 +/- 7% in patients without and with regional lymph node metastases, respectively.

[Assessment of different variants of hyperfractionated irradiation in cancer of the naso- and oropharynx and of the oral mucosa]. / Otsenka razlichnykh variantov giperfraktsionirovannogo oblucheniia raka nosorotoglotki i slizistoi obolochki rta.

The authors presented comparative analysis of the results of hyperfractionated gamma-irradiation of 75 patients with locally advanced head and neck tumors (stages II-IV) in various types of daily dose fractionation. 33 patients of the 1st group received radiotherapy at a dose of 1.2 Gy twice a day at a 6h-interval up to a total dose of 70-75 Gy, 23 patients of the 2nd group were irradiated at a dose of 1 Gy 3 times a day at a 3h-interval up to a total dose of 60-65 Gy, 19 patients of the 3rd group were irradiated at a dose of 1 Gy 5 times a day up to a total dose of 60 Gy. The authors have shown the prospects of hyperfractionated irradiation with two- and threefold daily dose fractionation in which complete tumor resorption was 94-95%, the 2-year survival was 60.6 +/- 7 and 75%, respectively without signs of late complications.

[Combination gamma-therapy of cancer of the oral mucosa]. / Sochetannaia gamma-terapiia raka slizistoi obolochki rta.

The authors analysed the results of therapy of 72 oral mucosa cancer patients who had received combined modality radiotherapy using at the stage of intracavitary irradiation sources of 60Co of a raised dose rate on the afterloading AGAT unit. Forty four patients received irradiation as part of combined modality therapy, 28 were treated by irradiation only. Two variants of combined modality radiotherapy were employed: gamma-beam and intracavitary irradiation was given simultaneously on the same day; consecutively alternating gamma-beam (on the 1st day) and intracavitary (on the 2nd day) irradiation. The most effective summary focal dose values in preoperative combined irradiation were 40-45 Gy (with the ratio of the contribution of gamma-beam therapeutic doses of 30-35 Gy and intracavitary doses of 10-15 Gy) and in radiotherapy used alone 75-80 Gy (with the ratio of irradiation components being 50-55 Gy and 25-30 Gy respectively). Complete tumor resorption in combined modality radiotherapy used independently was achieved in 19 out of 28 patients (67.8%). In combined treatment tumor regression by more than 50% after preoperative irradiation was achieved in 65.9% of the patients. Tumor recurrences were noted in 5 of 44 (11.3%) patients in combined treatment and in 3 out of 19 (15.7%) in radiotherapy used alone. Five-year survival rates calculated with the help of life tables were 55.7 +/- 10% after combined treatment and 48.7 +/- 11% after radiotherapy used alone. Clinical evidence indicated the advantages of combined modality radiotherapy with simultaneous intracavitary and gamma-beam irradiation.